author-photo

Frank S. Wu

GlaxoSmithKline

10

Papers

3341

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

2020 Blood
Show All
- Source
- Cite
- Save
Citations (9)
A phase I, first-in-human, dose-escalation and dose-expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (187)
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (38)
MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC).

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (20)
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).

2012 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (24)
Improved survival with MEK inhibition in BRAF-mutated melanoma.

2012 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (1680)